Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity

详细信息    查看全文

• 作者：Hodge ; James W. ; Grosenbach ; Douglas W. ; Schlom ; Jeffrey
• 关键词：Vaccines ; Tumor antigens ; Immunotherapy
• 刊名：Cancer Detection and Prevention
• 出版年：2002
• 出版时间：October, 2002
• 年：2002
• 卷：26
• 期：4
• 页码：275-291
• 全文大小：525 K

文摘

It has now been demonstrated in both experimental models and recent clinical trials that certain “self” antigens, which are functionally non-immunogenic in the host, can become immunogenic if presented to the immune system in a certain way. Here, we describe recombinant vaccines and vaccine strategies that have been developed to induce and potentiate T-cell responses of the host to such self-antigens. These strategies include: (a) the use of recombinant poxvirus vectors in which the tumor-associated antigen (TAA) is inserted as a transgene. Recombinant vaccinia vaccines and recombinant avipox (replication-defective) vaccines have been employed to break tolerance to a self-antigen; (b) the use of diversified prime and boost strategies using different vaccines; and (c) the insertion of multiple T-cell co-stimulatory molecules into recombinant poxvirus vectors, along with the TAA gene, to enhance T-cell immune responses to the TAA and induce anti-tumor immunity.